CANbridge Life Sciences, a Beijing in-licensing company, was approved to start a China Phase Ib/III clinical study of CAN017 in esophageal squamous cell cancer (ESCC). CANbridge in-licensed global rights (ex-North America) to the candidate from Aveo Pharma two years ago in a $134 million deal. The trial acceptance triggers a $2 million milestone payment to Aveo. Earlier this year, CANbridge started China trials of CAN008, a treatment for glioblastoma multiforme (GBM).
Source: China Biotoday
